Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Michael Cecchini, MD

Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers

Contact Information

Michael Cecchini, MD

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Cecchini focuses on developing new treatments for patients living with advanced gastrointestinal cancers. His specific research includes leveraging innovating DNA damaging therapies as a strategy to enhance the immune response. He has participated as both a principal investigator or sub-investigator on more than 100 clinical trials. This includes cooperative group studies, industry studies, as well as investigator initiated clinical trials. He is also the national principal investigator for multiple studies. In addition to his clinical research, Dr. Cecchini collaborates with multiple laboratories to perform bench to bedside research to enhance treatment options for patients living with gastrointestinal cancers.

He currently receives research funding through his NIH K08 Career Development Award which is evaluating the relationship between DNA damage and the immune response for gastrointestinal cancers. He was also awarded a Young Investigator Award from the Conquer Cancer Foundation, during his fellowship.

Coauthors

Research Interests

DNA Repair; Gastrointestinal Neoplasms; Immunotherapy

Selected Publications

  • Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas CancerMokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
  • 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancersHarding J, Hofheinz R, Fernandez M, Kuboki Y, Rasco D, Cecchini M, Shen L, Archuadze S, Geng J, Haderk F, Pant S. 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers Annals Of Oncology 2022, 33: s706. DOI: 10.1016/j.annonc.2022.07.509.
  • Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancerLi C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakih M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer Communications Medicine 2022, 2: 90. PMID: 35856081, PMCID: PMC9287310, DOI: 10.1038/s43856-022-00155-y.
  • Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ) Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
  • Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Cecchini M, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Journal Of Clinical Oncology 2022, 40: 3535-3535. DOI: 10.1200/jco.2022.40.16_suppl.3535.
  • Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational StudyKalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
  • Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMABeech C, Walther Z, Cecchini M, Gibson J. Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMA Gastroenterology 2022, 162: s-889-s-890. DOI: 10.1016/s0016-5085(22)62107-3.
  • Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potentialGiner-Calabuig M, De Leon S, Wang J, Fehlmann TD, Ukaegbu C, Gibson J, Alustiza-Fernandez M, Pico MD, Alenda C, Herraiz M, Carrillo-Palau M, Salces I, Reyes J, Ortega SP, Obrador-Hevia A, Cecchini M, Syngal S, Stoffel E, Ellis NA, Sweasy J, Jover R, Llor X, Xicola RM. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential British Journal Of Cancer 2022, 126: 1595-1603. PMID: 35197584, PMCID: PMC9130322, DOI: 10.1038/s41416-022-01754-1.
  • A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers.Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, Dowling E, Archuadze S, de Pereira B, Pant S. A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2022, 40: tps222-tps222. DOI: 10.1200/jco.2022.40.4_suppl.tps222.
  • A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.Gabrail N, Tolcher A, Alese O, Cecchini M, Manish P, Park H, Berlin J, Hamilton E, Huang Y, Lu L, Wang J, Shi M, Tong M. A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2022, 40: tps375-tps375. DOI: 10.1200/jco.2022.40.4_suppl.tps375.
  • Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital SystemPatel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, DOI: 10.21037/jgo-21-202.
  • Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer.Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
  • Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
  • Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdominal Radiology 2021, 46: 5609-5617. PMID: 34557934, DOI: 10.1007/s00261-021-03284-5.
  • A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.Patel M, Naing A, Burris H, Lin C, Curigliano G, Thistlethwaite F, Minchom A, Ascierto P, De Braud F, Cecchini M, Hanekom W, Sainson R, Wilson R, Quaratino S. A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. Journal Of Clinical Oncology 2021, 39: 2624-2624. DOI: 10.1200/jco.2021.39.15_suppl.2624.
  • Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.Desai J, Fakih M, Pedersen K, Hong Y, Segal N, Allen S, Bailey L, Lenain C, Lu D, Sayyed P, Schulze J, Cecchini M. Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer. Journal Of Clinical Oncology 2021, 39: 82-82. DOI: 10.1200/jco.2021.39.3_suppl.82.
  • Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.Uhlig J, Stein S, Lacy J, Cecchini M, Kim K. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Journal Of Clinical Oncology 2021, 39: 462-462. DOI: 10.1200/jco.2021.39.3_suppl.462.

Clinical Trials

ConditionsStudy Title
Phase IA Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Phase IOpen Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors
Phase IA Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
Phase IA Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Phase IA Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Phase IPhase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
Phase IA Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Phase IA Phase 1/2, Dose Escalation and Expansion Study of the Safety, Tolerability, and Anti-tumor Activity of BND-22 Administered Alone and in Combination With Pembrolizumab or With Cetuximab in Patients With Advanced Solid Tumors
Other Endocrine System; PancreasRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Phase IA Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Colon; Esophagus; Liver; PancreasAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Phase IA Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors
Phase IA Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients With Advanced Solid Tumors
Phase IA Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Phase IPhase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients With Advanced Solid Tumors (MYTHIC Study)
PancreasA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
LiverA Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Phase IA Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Phase IPhase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)
LungBAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
Edit Profile